A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Candidiasis, Esophageal; HIV Infections
Intervention: L-743,872 (Drug)
Phase: N/A
Status: Completed
Sponsored by: Merck Sharp & Dohme Corp.
Summary
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal
esophagitis, an AIDS-related yeast infection in the esophagus.
Clinical Details
Official title: An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis
Study design: Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment
Detailed description:
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of
three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the
final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria
You may be eligible for this study if you:
- Are an 18- to 65-year-old man with candidal esophagitis.
Locations and Contacts
Gary Calandra, Rahway, New Jersey 07065, United States
Additional Information
Last updated: June 23, 2005
|